Effect of continuous blood purification on the treatment of patients with septic shock and its influence on PCT and hs-CRP
Objective To study the effect of continuous blood purification on patients with septic shock and its influence on procalcitonin(PCT),hypersensitive C-reactive protein(hs-CRP).Methods A total of 80 patients with septic shock admitted to the First People's Hospital of Mengcheng County from January 2019 to April 2023 were selected for this study.They were randomly divided into control group(n=40)and experimental group(n=40).The control group received hemodialysis treatment,and the experimental group received continuous blood purification treatment.Serum PCT,hs-CRP,partial pressure of carbon dioxide(PaCO2),pH,acute physiologic and chronic health status scoring system Ⅱ(APACHEⅡ),sequential organ failure estimation(SOFA)score,and clinical efficacy,28 d mortality and length of ICU stay measures were compared between the two groups.Results There were no significant differences in serum PCT,hs-CRP,PaCO2,pH,APACHE Ⅱ and SOFA scores between the two groups before treatment(all P>0.05).After treatment,serum PCT,hs-CRP,PaCO2,pH,APACHE Ⅱ and SOFA score measures were significantly decreased in both groups,and those in the experimental group were lower than those in the control group;the differences were statistically significant(t=7.771,8.769,4.205,75.661,5.579,8.495;all P<0.05).After treatment,the total effective rate of experimental group(77.50%)was higher than that of control group(55.00%);the difference was statistically significant(x2=4.528,P=0.033);the 28 d mortality and ICU stay time of the experimental group[5.00%,(8.02±2.31)d]were significantly lower than those of the control group[(22.50%,(11.14±5.04)d],the differences were statistically significant(x2=5.165,t=3.559;both P<0.05).Conclusion In septic shock patients,continuous blood purification therapy had a certain effect,which could effectively improve the serum PCT and hs-CRP levels.
Continuous blood purificationSeptic shockProcalcitoninHypersensitive C-reactive protein